Efgartigimod Alfa: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
ZIN (Netherlands) recommended or restricted efgartigimod alfa, while AOTMIT (Poland), DMC (Denmark) and NYE METODER (Norway), among others, did not recommend it.
The record spans 4.2 years, opening at CHUIKYO (Japan) on 13 Apr 2022 and running to 2026.
PBAC (Australia) changed its position: recommended in 2025, not recommended by 2026.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 17 of 20 records date from 2023 or later.
Against its own class, efgartigimod alfa is an outlier: 56% of its decisive outcomes were positive, where molecules sharing ATC class L04A average 78%.
4 distinct indication wordings are recorded for efgartigimod alfa by the agencies that label one in English (AWMSG, PBAC and SMC).
3 of these 20 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
CHUIKYO (Japan) was first to assess efgartigimod alfa, on 13 Apr 2022; PBAC (Australia) did not open a file until 2025 — a wide spread of 3.2 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 5 years in total.
4 of the 11 agencies here assessed efgartigimod alfa more than once, CIPM (Spain) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for efgartigimod alfa.
The full ledger for efgartigimod alfa reads 9 recommended, 7 not recommended, 2 no benefit and 1 deferred to NICE, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2026 | Chronic inflammatory demyelinating polyneuropathy (CIDP) | Not Recommended | source |
| HAS (France) | 15 Apr 2026 | Listing (Transparency Committee) | SMR moderate · ASMR V | source |
| G-BA (Germany) | 22 Jan 2026 | Vyvgart — benefit assessment §35a | added benefit: not proven | source |
| CIPM (Spain) | 16 Jul 2025 | Indicaciones terapéuticas autorizadas: Vyvgart está indicado como complemento de la terapia estándar para el tratamiento… | financed by the SNS · art. 92 a, c | source |
| NYE METODER (Norway) | 25 Aug 2024 | Som et tillegg til standardbehandling for behandling av voksne med generalisert myasthenia gravis (gMG) som er anti-acet… | not introduced | source |
15 further decisions for efgartigimod alfa, across 10 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 12 further source documents.
Related molecules
- ravulizumab — divergent outcome (recommended vs not recommended) on a shared indication
- human normal immunoglobulin — divergent outcome (recommended vs not recommended) on a shared indication
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
Coverage: 20 decisions for efgartigimod alfa from 11 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.